D.T.L. Jones
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
D.T.L. Jones has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
J. E. Symons
Division of Medical Radiation, National Accelerator Centre, Faure, South Africa
2 shared publicationsA Serafin
1 shared publicationA. Buffler
1 shared publication- A. Nicolaas Schreuder
National Accelerator Centre, Faure, South Africa
1 shared publication A.N. Schreuder
Medical Radiation Group, National Accelerator Centre, PO Box 72, Faure, 7131 South Africa
1 shared publicationClare E. Stannard
Groote Schuur Hospital, Observatory, South Africa
1 shared publication
Latest Publications
- 1 June 2001
- Published by Elsevier in Radiation Physics and Chemistry
- Vol. 61 (3-6) , 615-618
Magnetically scanned proton therapy beams: rationales and principles
- 1 June 2001
- Published by Elsevier in Radiation Physics and Chemistry
- Vol. 61 (3-6) , 615-618
Magnetically scanned proton therapy beams: rationales and principles
- 1 June 1999
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 175 (S2) , 30-32
Status report of the NAC particle therapy programme
Summary The 200 MeV cyclotron facility at the National Accelerator Centre has been operational since 1987. Between September 1988 and December 1997 a total of 973 patients (26,916 fields) had been treated on the 66 MeV p+Be isocentric neutron therapy system. Patients are currently being treated according to several protocols, including tumors of the head and neck, salivary gland and breast and soft tissue sarcomas, uterine sarcomas and paranasal sinuses. A multiblade post-collimator trimmer has recently being installed. This device procides improved neutron beam shaping capability. Between September 1993 and December 1997 a total of 243 patients (4008 fields) had been treated (mainly intracranial stereotactic irradiations) on the fixed horizontal 200 MeV proton therapy facility. The facility incorporates an innovative automatic patient positioning system. Two new fixed beam lines for proton therapy are presently being designed (horizontal and 30° to the vertical) for an existing unused treatment vault. Spot scanning systems will be developed for both beam lines.
- 1 June 1999
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 175 (S2) , 30-32
Status report of the NAC particle therapy programme
Summary The 200 MeV cyclotron facility at the National Accelerator Centre has been operational since 1987. Between September 1988 and December 1997 a total of 973 patients (26,916 fields) had been treated on the 66 MeV p+Be isocentric neutron therapy system. Patients are currently being treated according to several protocols, including tumors of the head and neck, salivary gland and breast and soft tissue sarcomas, uterine sarcomas and paranasal sinuses. A multiblade post-collimator trimmer has recently being installed. This device procides improved neutron beam shaping capability. Between September 1993 and December 1997 a total of 243 patients (4008 fields) had been treated (mainly intracranial stereotactic irradiations) on the fixed horizontal 200 MeV proton therapy facility. The facility incorporates an innovative automatic patient positioning system. Two new fixed beam lines for proton therapy are presently being designed (horizontal and 30° to the vertical) for an existing unused treatment vault. Spot scanning systems will be developed for both beam lines.
- 1 October 1996
- Vol. 172 (10) , 567-72
Radiosensitivity variations in human tumor cell lines exposed in vitro to p(66)/Be neutrons or 60Co gamma-rays.
Neutron therapy should be beneficial to patients with tumor types which are resistant to photons but relatively sensitive to high-LET radiation. In this work the potential therapeutic gain of a clinical neutron beam is evaluated by quantifying the variations in radiosensitivity of different cell lines to neutrons and photons. Different cell lines were exposed in vitro to p(66)/Be neutrons or 60Co gamma-rays. Micronuclei frequencies in binucleated cells and surviving fractions were determined for each cell type. Following exposure to either 1 or 1.5 Gy neutrons, micronuclei frequencies were significantly correlated with that observed for 2 Gy photons. A weak but significant correlation between the variation in neutron RBE values, determined from survival curve inactivation parameters and the mean inactivation doses for photon exposures, was also established. It is concluded that although neutron and photon sensitivities are related, the use of this high energy neutron source may constitute a potential therapeutic gain for tumor types that can be identified as very resistant to photons. Considering that a definitive oxygen gain factor has been established for this neutron beam the observed therapeutic gain is expected to be further enhanced in tumors where hypoxia protects cells from conventional radiation damage.
- 1 October 1996
- Vol. 172 (10) , 567-72
Radiosensitivity variations in human tumor cell lines exposed in vitro to p(66)/Be neutrons or 60Co gamma-rays.
Neutron therapy should be beneficial to patients with tumor types which are resistant to photons but relatively sensitive to high-LET radiation. In this work the potential therapeutic gain of a clinical neutron beam is evaluated by quantifying the variations in radiosensitivity of different cell lines to neutrons and photons. Different cell lines were exposed in vitro to p(66)/Be neutrons or 60Co gamma-rays. Micronuclei frequencies in binucleated cells and surviving fractions were determined for each cell type. Following exposure to either 1 or 1.5 Gy neutrons, micronuclei frequencies were significantly correlated with that observed for 2 Gy photons. A weak but significant correlation between the variation in neutron RBE values, determined from survival curve inactivation parameters and the mean inactivation doses for photon exposures, was also established. It is concluded that although neutron and photon sensitivities are related, the use of this high energy neutron source may constitute a potential therapeutic gain for tumor types that can be identified as very resistant to photons. Considering that a definitive oxygen gain factor has been established for this neutron beam the observed therapeutic gain is expected to be further enhanced in tumors where hypoxia protects cells from conventional radiation damage.
- 1 May 1995
- Published by Wiley in Medical Physics
- Vol. 22 (5) , 597-599
Directional characteristics of neutrons from the p(66)/Be(40) reaction
- 1 May 1995
- Published by Wiley in Medical Physics
- Vol. 22 (5) , 597-599
Directional characteristics of neutrons from the p(66)/Be(40) reaction
- 1 January 1995
- Published by Wiley in Medical Physics
- Vol. 22 (1) , 23-24
Evaluation of kerma ratios in a p (66)/Be(40) neutron therapy beam
- 1 January 1995
- Published by Wiley in Medical Physics
- Vol. 22 (1) , 23-24
Evaluation of kerma ratios in a p (66)/Be(40) neutron therapy beam